This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Protalix BioTherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

129.7%

Wachstumsrate der Gewinne

130.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	38.9%
Wachstumsrate der Einnahmen	34.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	28 Feb 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

TASE:PLX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2024	95	38	N/A	N/A	1
12/31/2023	63	8	N/A	N/A	1
12/31/2022	48	-15	-26	-25	N/A
9/30/2022	48	-18	-28	-27	N/A
6/30/2022	45	-18	-21	-20	N/A
3/31/2022	43	-24	-8	-6	N/A
12/31/2021	38	-28	-12	-10	N/A
9/30/2021	49	-21	-14	-13	N/A
6/30/2021	48	-21	-16	-14	N/A
3/31/2021	53	-14	-30	-29	N/A
12/31/2020	63	-7	-27	-26	N/A
9/30/2020	61	-7	-23	-22	N/A
6/30/2020	65	-6	-23	-22	N/A
3/31/2020	66	-9	-20	-19	N/A
12/31/2019	55	-18	-20	-19	N/A
9/30/2019	47	-24	-20	-20	N/A
6/30/2019	45	-26	-3	-3	N/A
3/31/2019	38	-26	-6	-6	N/A
12/31/2018	34	-26	-8	-8	N/A
9/30/2018	28	-34	13	14	N/A
6/30/2018	23	-40	-11	-10	N/A
3/31/2018	25	-32	-12	-11	N/A
12/31/2017	21	-83	-11	-10	N/A
9/30/2017	19	-73	-36	-35	N/A
6/30/2017	16	-69	-29	-28	N/A
3/31/2017	11	-80	-32	-31	N/A
12/31/2016	9	-29	-33	-32	N/A
9/30/2016	7	-35	N/A	-29	N/A
6/30/2016	4	-34	N/A	-34	N/A
3/31/2016	3	-29	N/A	-27	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PLX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Ertrag vs. Markt: PLX is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hohe Wachstumserträge: PLX is expected to become profitable in the next 3 years.

Einnahmen vs. Markt: PLX's revenue (34.4% per year) is forecast to grow faster than the IL market (4.6% per year).

Hohe Wachstumseinnahmen: PLX's revenue (34.4% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Protalix BioTherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings released: US$0.072 loss per share (vs US$0.092 loss in 3Q 2021)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.25 loss in 2Q 2021)

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings released: US$0.05 loss per share (vs US$0.14 loss in 1Q 2021)

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

President recently bought ₪328k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings released: US$0.63 loss per share (vs US$0.22 loss in FY 2020)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: ₪15.05

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: ₪13.60

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

New 90-day low: ₪11.03

Third quarter earnings released

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

New 90-day high: ₪13.79

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

New 90-day low - ₪11.41

New 90-day low - ₪11.66

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken